Evidence map›Paper›PMID 37719938›Full record

ArticleJournal of inflammation research2023

Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma.

Yongzhen Zhou, Chenjie Qiu, Qingsheng Fu, Tao Li, Xudong Zhang, Chunfu Zhu, Xihu Qin, Baoqiang Wu

Abstract read
In one paragraph

Article in Journal of inflammation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yongzhen Zhou *Department of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China.
Chenjie Qiu *Department of General Surgery, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, 213000, People's Republic of China.
Qingsheng FuGraduate School, Bengbu Medical College, Bengbu, 233003, People's Republic of China.
Tao LiDepartment of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China.
Xudong ZhangDepartment of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China.
Chunfu ZhuDepartment of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China.
Xihu QinDepartment of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China.
Baoqiang WuDepartment of General Surgery, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: RAD54L is a prominent member of the SWI2/SNF2 protein family, primarily involved in the homologous recombination repair (HRR) process, thereby playing a pivotal role in the repair of DNA double-strand breaks (DSBs). RAD54L has been implicated in the development of numerous tumors. Consequently, we aimed to investigate the potential contribution of RAD54L in pan-cancer. Methods: Various databases and analytical tools were employed for bioinformatics analysis. Moreover, in vitro experiments were conducted to corroborate the findings from the bioinformatics analysis and delve deeper into the role of RAD54L in hepatocellular carcinoma (HCC). Results: RAD54L expression demonstrated a significant elevation in the majority of tumors, and its overexpression was strongly associated with unfavorable survival outcomes. RAD54L displayed robust correlations with the infiltration levels of various immune cells, including cancer associated fibroblasts (CAFs), endothelial cells, and myeloid-derived suppressor cells (MDSCs). Additionally, associations were observed between RAD54L and key factors such as tumor mutation burden (TMB), microsatellite instability (MSI), multiple immune checkpoints, and immune cell infiltration. Moreover, a close relationship was observed between RAD54L expression levels in HCC and clinicopathological characteristics, as well as immune cell infiltration. Experimental techniques including qRT-PCR, Western blotting, colony-forming, Cell Counting Kit-8 (CCK-8), wound-healing, and transwell assays were employed, which collectively demonstrated that RAD54L promoted the proliferation and migration of HCC cells. Conclusion: RAD54L exhibits robust expression in both pan-cancer and HCC, exerting a significant influence on the proliferation and migration of HCC cells. These findings highlight its potential as a promising biomarker for pan-cancer and a prospective target for immunotherapy.

Indexed as

malignant behaviorpan-cancerRAD54Ltumor microenvironment

Identifiers

PMID37719938
PMCPMC10503553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.